The Amgen Q3 2024 Earnings Call discussed the company's performance, pipeline updates, and growth strategies across core therapeutic areas. Highlights included strong revenue growth, progress in rare diseases, and advancements in pipeline medicines like MariTide and TEZSPIRE.